Key facts
- This page summarizes Tamara A. Favorito's Form 4 filing for ARTELO BIOSCIENCES, INC. (ARTL).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 May 2025, 17:24.
Tamara A. Favorito - 01 May 2025 Form 4 Insider Report for ARTELO BIOSCIENCES, INC. (ARTL)
- Reporting relationship
- Director
- Issuer ticker
- ARTL
- Reported as of
- 01 May 2025
- Net transaction value
- +$25,000
- SEC form
- 4
- Accepted by SEC
- 05 May 2025, 17:24:07 UTC
- Prior SEC filing
- 23 Dec 2024
- Next SEC filing
- 30 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gregory D. Gorgas, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Tamara A. Favorito filed Form 4 for ARTELO BIOSCIENCES, INC. (ARTL) on 05 May 2025.
Change
- Previous filing in this sequence was filed on 23 Dec 2024.
- Current net transaction value: +$25,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001288232
Primary reporting owner
FAVORITO TAMARA A
- Relationship
- Director
- Address
- C/O ARTELO BIOSCIENCES, INC., 505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH
- Signature
- /s/ Gregory D. Gorgas, as Attorney-in-Fact
- Signature date
- 05 May 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARTL
transaction
Derivative
Convertible Promissory Note
Purchase
- Transaction value
- $25,000
- Shares
- Change %
- Price
- Shares after
- $25,000
- Date
- 01 May 2025
- Ownership
- By trust
- Underlying class
- Common Stock
- Underlying amount
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On or about May 1, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") with the Reporting Person, pursuant to which the Issuer issued a convertible note (the "Note") to the Reporting Person. The Notes will accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default (as defined in the Note). All unpaid principal, together with any then unpaid and accrued interest and other amounts payable thereunder, shall be due and payable on October 28, 2025 (the "Maturity Date").
Footnote F2
At the Maturity Date, the Reporting Person may (at the Reporting Person's sole option) convert all of that certain unpaid portion of principal and accrued interest of the Reporting Person's Note into shares of the Issuer's common stock ("Common Stock") (the "Voluntary Conversion"), specifically into that number of shares of Common Stock (the "Converted Shares") equal to the unpaid principal balance and any accrued interest of each Note divided by $1.29. The amount of principal balance and any accrued interest of the Note convertible pursuant to the Voluntary Conversion shall be the number of Converted Shares multiplied by $1.04 (the "Minimum Price"). Should the Reporting Person not elect Voluntary Conversion, such portion of the unpaid principal balance and any accrued interest of the Note subject to Voluntary Conversion shall be immediately due and payable in cash.
Footnote F3
At the Maturity Date, that portion of the unpaid principal balance and any accrued interest of the Note not subject to the Voluntary Conversion shall be automatically converted into a warrant to purchase shares of the Issuer's Common Stock (the "Warrant") at a conversion price of $0.125 per share issuable pursuant to the Warrant (the "Automatic Conversion"). The exercise price of such Warrant for each Warrant Share shall be equal to the Minimum Price.